Jyong Biotech (NASDAQ:MENS) Shares Gap Up - Still a Buy?

Key Points

• Large gap and volume: Jyong Biotech (NASDAQ:MENS) gapped up premarket from $3.17 to $3.45 and was last reported at $7.46 on heavy volume (~11.7M shares), signaling a dramatic intraday move.
• Analyst sentiment is negative: Weiss Ratings reissued a "sell (e+)" and MarketBeat shows a consensus Sell rating for the stock.
• Limited institutional interest and technical disconnect: BNP Paribas initiated a small position of 1,698 shares (~$67K), while the stock trades far below its 50‑day SMA of $36.97, highlighting volatility and a disconnect from recent averages.

Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report)'s share price gapped up prior to trading on Monday . The stock had previously closed at $3.17, but opened at $3.45. Jyong Biotech shares last traded at $7.46, with a volume of 11,721,070 shares changing hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Jyong Biotech in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of "Sell".

Jyong Biotech Price Performance

The company has a fifty day simple moving average of $36.97.

Hedge Funds Weigh In On Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets acquired a new position in shares of Jyong Biotech Ltd. (NASDAQ:MENS - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,698 shares of the company's stock, valued at approximately $67,000.

Jyong Biotech Company Profile

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.